Overview

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic Squamous Cell Carcinoma in Head and Neck (SCCHN) in Asian subjects.

Phase:

Phase 3

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Cetuximab
Cisplatin
Fluorouracil